Our findings underscore the significance of the O-GlcNAcylation-METTL3-MCM10-IGF2BP3 regulatory axis in HCC development and highlight the potential of targeting this modification for therapeutic gain. This evidence concerns the gene IGF2BP3 and hepatocellular carcinoma.